Trial Information
Phase II Study of Sunitinib in Metastatic Renal Cancer With Non-clear Cell Histology
Inclusion Criteria:
- Histologically proven diagnosis of metastatic renal cancer with non-clear cell
- No previous treatment
Exclusion Criteria:
- Prior treatment with an antiangiogenetic compound
- Symptomatic and/or unstable pre-existing brain metastases
- Severe or uncontrolled cardiovascular diseases
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
The antitumor activity in terms of progression free survival
Outcome Time Frame:
two years
Safety Issue:
No
Principal Investigator
Armando Santoro, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Istituto Clinico Humanitas
Authority:
Italy: Ministry of Health
Study ID:
ONC-2008-004
NCT ID:
NCT01034878
Start Date:
December 2009
Completion Date:
November 2011
Related Keywords:
- Metastatic Renal Cancer With Non-clear Cell
- Carcinoma, Renal Cell
- Kidney Neoplasms